← Back to headlines
Recursion outlines 2026 cash OpEx guidance and advances Genentech target
Recursion has outlined its 2026 cash operating expenses guidance at $375 million. The company is also advancing its first neuroscience target in collaboration with Genentech.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
S&P, Nasdaq end lower after Fed Chair Warsh reaffirms inflation fight - Reuters
38m ago
Former RTÉ Presenter Keith Walsh Sues Broadcaster Over Unfair Dismissal Claims
3h ago
Glencore Takes $480 Million Provision on Radiant World Exposure
3h ago
US Treasury Warns Yen Volatility Could Destabilize Global Markets
3h ago